Werewolf Therapeutics, Inc.
HOWLHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeWerewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other. The company carries a $47.0M market cap, placing it firmly in the micro-cap category. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.
Market Cap
$47.0M
Beta
0.51
P/E (TTM)
—
P/E (Fwd)
-1.64
EPS (TTM)
$-0.74
EPS (Fwd)
$-0.59
ROE
-119.9%
ROA
-27.4%
Cash
$22.0M
Total Debt
$0
Free CF
-$12.2M
52W Change
-27.4%
Annual Financials
Cash vs Debt
Where HOWL stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, HOWL finished 66.67% above its 150-day moving average ($0.60) and 53.85% above its 200-day moving average ($0.65). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HOWL overbought or oversold?
At the September 3, 2026 close, HOWL's RSI(14) was 93.2, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Werewolf Therapeutics, Inc. reports $22.0M in cash and $0 in total debt. Free cash flow is running at -$12.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -119.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $16.4M (2022) to $0 (2025), a 100% decline worth watching.
HOWL's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing HOWL.